RxDoctor Payments Data

Brendan McGuire

Hepatology · Birmingham, ALNPI 1336179688

Payments from drug & device makers

$186,358in general payments, 2019–2025

Across 125 payments — averaging $1490.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Grifols Therapeutics LLC$43K
  • Mallinckrodt Hospital Products Inc.$36K
  • Alnylam Pharmaceuticals Inc.$35K
  • Bausch Health US, LLC$33K
  • Gilead$17K
  • Mallinckrodt Enterprises LLC$7K
  • plus $16K from 14 others

What the payments were for

  • Consulting fees$11,13549%
  • Speaking & faculty fees$9,33041%
  • Travel & lodging$3462%
  • Food & beverage$1,8348%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few hepatology providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$63,705
Medicare patients
296
Services billed
769

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin156$569,279
VemlidyTenofovir Alafenamide58$90,817
Ursodiol135$34,851
EliquisApixaban27$19,681
Mycophenolic AcidMycophenolate Sodium28$18,727
Tacrolimus214$15,399
Mycophenolate Mofetil125$15,124
Everolimus13$11,903
Cyclosporine13$9,965
Entecavir17$7,393
Cyclosporine ModifiedCyclosporine, Modified39$6,797
Lactulose53$2,725
Tenofovir Disoproxil Fumarate31$1,783
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen60$1,716
Nadolol25$1,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$187$569,279156 claims
GileadVemlidy$17,493$90,81758 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hepatology providers in Alabamaon file to place this against a meaningful peer group, so we don't.

Other hepatology in Birmingham

Where these figures come from

Is this you, or does something look wrong? →